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In December 2008, the U.S. Food and Drug Administration issued guidance to
the pharmaceutical industry setting new expectations for the development of
antidiabetes drugs for type 2 diabetes. This guidance expanded the scope and cost
of research necessary for approval of such drugs by mandating long-term
cardiovascular outcomes trials (CVOTs) for safety. Since 2008, 9 CVOTs have been
reported, 13 are under way, and 4 have been terminated. Reassuringly, each of
the completed trials demonstrated the noninferiority of their respective drugs to
placebo for their primary cardiovascular (CV) composite end point. Notably, four
additionally provided evidence of CV benefit in the form of significant decreases in
the primary CV composite end point, two suggested reductions in CV death, and
three suggested reductions in all-cause mortality. Although these trials have
yielded much valuable information, whether that information justifies the
investment of time and resources is controversial. In June 2016, a Diabetes Care
Editors’ Expert Forum convened to review the processes and challenges of CVOTs,
discuss the benefits and limitations of their current designs, and weigh the merits of
modifications that might improve the efficiency and clinical value of future trials.
Discussion and analysis continuedwith the CVOT trial results released in June 2017 at
theAmericanDiabetes Association’s Scientific Sessions and in September 2017 at the
European Association for the Study of Diabetes scientific meeting. This article sum-
marizes the discussion and findings to date.
In December 2008, theU.S. Food andDrugAdministration (FDA) issued guidance to the
pharmaceutical industry setting out new expectations for the development of antidia-
betes drugs for type 2 diabetes (1). This guidance focused specifically on cardiovascular
(CV) safety, largely in recognition of the excess burden of cardiovascular disease (CVD)
in type 2 diabetes (2). The FDA was responding to prevailing concerns about the
potential for increased CVD risk associated with certain antidiabetes drugs, notably
the thiazolidinedione (TZD) rosiglitazone (3,4). The guidancedand subsequent similar
requirements from the European Medicines Agency (5)deffectively expanded the
scope and cost of research necessary to secure approval of new antidiabetes drugs
by mandating long-term safety trials.
In the 9 years since the guidance was issued, 9 long-term, prospective CV outcomes
trials (CVOTs) have been completed, 13 are under way, and 4 were started but termi-
nated early. Collectively, these studies have involved more than 190,000 participants.
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The nine completed trials examined three
dipeptidyl peptidase 4 (DPP-4) inhibitors
(6–8), four glucagon-like peptide 1 (GLP-
1) receptor agonists (9–12), and two
sodium–glucose cotransporter 2 (SGLT2)
inhibitors (13,14). Each demonstrated the
noninferiority of their respective drugs to
placebo in their major adverse cardiac
event (MACE) primary composite end
point. Four additionally provided evi-
dence of CV benefit in the form of signif-
icant decreases in the MACE primary
composite end point (10,11,13,14), two
found reductions in CV death (10,13),
and three showed reductions in all-cause
mortality (10,12,14)dalthough the sta-
tistical robustness of findings for these
secondary end points in some cases may
be controversial.
The completed CVOTs have provided
much valuable information, and because
numerous antidiabetes drugs have been
developed and tested in the past decade,
it appears that the FDA mandate has not
discouraged pharmaceutical companies
from pursuing approval for potentially
successful drugs. Still, questions remain
regarding whether the information ob-
tained throughCVOTs designed according
to the FDAmandate justifies the time and
resources needed, especially in light of
the neutral results ofmany of the studies.
In June2016,aDiabetesCareEditors’ Expert
Forum convened and began to review the
processes and challenges of CVOTs, dis-
cuss the benefits and drawbacks of their
current designs, and weigh the merits of
potential modifications that might im-
prove the efficiency and clinical value of
future trials. This process continued
through September 2017 to include addi-
tional CVOTdata reported at that time. This
article summarizes the proceedings of the
Expert Forum and CVOT findings to date.
PRE-GUIDANCE RESEARCH AND
CONTROVERSY
Recent data indicate that, because of ad-
vances in research and clinical care, morbid-
ityandmortalityhavedecreasedsignificantly
inboth type1and type2diabetes.However,
individualswithdiabetes still havegreaterCV
risk than those without diabetes (15). Thus,
additional strategies to reduce this risk
continue to be evaluated.
Well before 2008, diabetes was known
tomore than double the risk for CV events
and was considered by some a coronary
artery disease equivalent (16). Although
several major clinical trials ofmore versus
less stringent glycemic control initially
failed to demonstrate that intensive glu-
cose lowering significantly reduces CV risk
(17–23), meta-analyses indicated a mod-
estly reduced risk of nonfatal myocardial
infarction (MI) (24,25). In addition, long-
term noninterventional follow-up of the
DCCT (Diabetes Control and Complica-
tions Trial) (26,27) in type 1 diabetes
and the UKPDS (UK Prospective Diabetes
Study) (28) and VADT (Veterans Affairs
Diabetes Trial) (29) in type 2 diabetes sug-
gested an eventual “legacy” CV benefit of
initially tighter glycemic control (Table 1)
(17–22,26–30), but one that was not as
apparent as the effect on microvascular
complications. However, increased CV
mortality in patients assigned to a more
intensive glucose-lowering strategy in the
ACCORD (Action to Control Cardiovascu-
lar Risk in Diabetes) trial (20,30) and no
reduction in CVmortality risk in the VADT
(22,29) tempered enthusiasm for strin-
gent glucose lowering, particularly in
older patients at high CV risk.
Less well understood was the CV safety
profile of available antidiabetes drugs. Be-
fore the FDA issued its 2008 guidance, ap-
proval decisions for such medications
focused largely on short-term glycemic ef-
ficacy (i.e., A1C reduction), along with
safety data from 6- to 12-month phase
2 and 3 randomized clinical trials. These
trials typically enrolled younger cohorts
with relatively recent onset of diabetes
and low CV risk. Indeed, individuals with
established CVD were usually excluded.
Thus, these studies had low CV event
rates, and the events that did occur were
neither prespecified as end points nor in-
dependently adjudicated. As a result, esti-
mates of theCV safety of thesedrugswere
inconsistent and unreliable (31,32).
Concerns about this gap in assessment
of CV safety grew after two highly contro-
versialmeta-analysesofCV risk (3,33)were
published in the mid-2000sdthe first on
muraglitazar, an investigational dual per-
oxisome proliferator–activated receptor
(PPAR)-a and -g agonist, and the second
on the FDA-approved TZD (and PPAR-g
agonist) rosiglitazone. The muraglitazar
analysis showed more than twice the in-
cidence of CV complications, including
congestive heart failure (HF) and death,
with the drug compared with standard
therapy (33). Although this drug had re-
ceived a vote for approval from the FDA’s
Endocrinologic and Metabolic Drugs Ad-
visory Committee (34), these findings ef-
fectively ended its development. The
meta-analysis of rosiglitazone, which had
already been marketed for a decade,
suggested a statistically significant 43%
increased risk of MI and a statistically
nonsignificant 64% increased risk of CV
death versus comparators (3). In the
wake of these publications and the heated
Table 1—Early major trials evaluating the effects of intensive glycemic control of diabetes
Study Diabetes type CV composite MI CV mortality All-cause mortality
DCCT/EDIC (17,26,27) Type 1 ↔ ↓ d d d d ↔ ↓
UKPDS Type 2
Main randomization (SUor insulin vs. conventional therapy)
(18,28) d d ↔ ↓ d d ↔ ↓
Additional randomization of overweight patients
(metformin vs. SU vs. conventional therapy) (19,28) d d ↓* ↓* d d ↓* ↓*
ACCORD (20,30) Type 2 ↔ ↔ ↓ ↔ ↑ ↑ ↑ ↔
ADVANCE (21) Type 2 ↔† ↔ ↔ ↔
VADT (22,29) Type 2 ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
Left columns show initial results; right columns show long-term follow-up.↔, Neutral effect; ↓, decrease; ↑, increase;d, not assessed/reported;
ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation; SU, sulfonylurea. Adapted from Bergenstal
et al. (97). *Metformin group only. †A decrease was reported in a combined CV/microvascular composite but was found to be mostly attributable to
nephropathy.
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controversy they ignited, the FDA issued
its CV safety guidance.
After a subsequent study specifically
designed to test the CV safety of rosiglitazone
did not confirm the earlier findings (35,36),
the FDA lifted its prescription restrictions
for rosiglitazone (37). Even so, use of ro-
siglitazone remains negligible. Trials of
another TZD, pioglitazone, have shown
CV benefit in high-risk patients. The PRO-
active (Prospective Pioglitazone Clinical
Trial in Macrovascular Events) study (38)
found that pioglitazone reduced the sec-
ondary composite end point of all-cause
mortality, nonfatal MI, and stroke in pa-
tients with type 2 diabetes who were at
high risk for macrovascular events. The
more recent IRIS (Insulin Resistance Inter-
vention After Stroke) trial (39,40) found
that, in insulin-resistant patients (many
with prediabetes but none with diabetes)
with previous ischemic stroke or transient
ischemic attack, treatment with this drug
significantly reduced fatal and nonfatal
MI and stroke.
REVIEW OF THE GUIDANCE
The FDA, following its usual process, cast
its expectations as recommendations
rather than requirements, but also noted
that theywere “for immediate implemen-
tation to ensure that relevant issues re-
lated tominimizing cardiovascular risk are
considered in ongoing drug development
programs” (1). The guidance outlined a
detailed process for evaluating the CV
safety of type 2 diabetes drugs in devel-
opment (Table 2) (1,41).
It was suggested that separate CVOTs
would be necessary only if meta-analyses
could not rule out an unacceptable level
of risk. However, the number ofCVevents
accrued during a typical phase 2 or 3 de-
velopment program is usually insufficient
toprovidehigh statistical confidence. Thus,
as noted in a review by Regier et al. (42),
every new antidiabetes drug approved
since 2008 has had a dedicated CVOT to
evaluate whether the upper limit of a
two-sided 95% CI of the estimated hazard
ratio (HR) is ,1.8, the requirement nec-
essary to gain initial approval. Although
the FDA’s guidance specifically excluded
insulin from its CV safety evaluation, not-
ing that its necessity as a lifesaving therapy
for type 1 diabetes makes such evaluation
impractical, some newer insulin formula-
tions have been studied in CVOT trials
based on findings from meta-analysis of
phase 2 and 3 studies (43).
SUMMARY OF CVOTS TO DATE
Trial Designs
Figure 1 displays a timeline of completed
and ongoing diabetes CVOTs, as well as
several related trials that assessed CV
outcomes but were not initiated as a di-
rect result of the 2008 FDA guidance
(6–14,39,44–58). These trials weremainly
designed to rule out unacceptable CV risk,
but some were powered to estimate su-
periority after noninferiority was dem-
onstrated. They typically have studied
populations in which some or all patients
had advanced atherosclerotic CV risk or
established CVD to ensure accrual of
sufficient events in a timely manner.
Some had active run-in periods to en-
hance adherence to the study drug. Their
participants have a long duration of dia-
betes (mean 7.1–16.4 years), with base-
line mean A1C ranging from 7.2 to 8.7%.
The characteristics of the completed
CVOTs and their primary findings are
summarized in Table 3 (6–14,59,60). On-
goingCVOTsaresummarized inSupplementary
Table1 (44–56), and SupplementaryTable2
summarizes additional trials that assessed
CV outcomes but were not initiated as a
direct result of the 2008 FDA guidance
(39,57,58,61).
Most of the CVOTs were designed as
phase4event-driven trials requiring.600
primary end point events to rule out with
statistical confidence anHRwith anupper
confidence limit$1.3 for a 3-point MACE
(CV death, nonfatal MI, and nonfatal
stroke). In three trials (TECOS [Trial Eval-
uating Cardiovascular Outcomes with
Sitagliptin] [8], ELIXA [Evaluation of
Lixisenatide inAcute Coronary Syndrome]
[9]), and FREEDOM-CVO [A Study to Eval-
uate Cardiovascular Outcomes in Patients
With Type 2 Diabetes Treated With ITCA
650] [53]) a 4-point MACE, adding hos-
pitalization for unstable angina to the
components of the 3-point MACE, is the
primary end point. In the ACE (Acarbose
Cardiovascular Evaluation) trial (58) of the
a-glucosidase inhibitoracarbose,conducted
in China in patients with coronary heart
disease and impaired glucose tolerance
(IGT), the primary end point is a 5-point
MACE, adding hospitalization for unstable
Table 2—Summary of the 2008 FDA guidance on CVOTs (1)
To adequately evaluate the CV safety of type 2 diabetes drugs in development, future development programs should include:
c Phase 2 and 3 trials that include patients at higher risk for CV events, are of sufficient size and duration to enable enough CV events to allow for a
meaningful evaluation of CV risk, and are designed to facilitate latermeta-analysis; the CV events should include CVmortality,MI, and stroke and can
also include hospitalization for ACS, urgent revascularization procedures, and other end points such as HF hospitalization*
c Independent adjudication of CV events
c Meta-analysis of the phase 2 and 3 trials to be conducted at the end of the research program, following a protocol developed in advance that
prespecifies the end points to be assessed and the statistical methods to be employed
cAnalysis of premarketing data comparing the CVevents occurringwith the agent to those occurringwith the control group and demonstrating that the
upper limit of a two-sided 95% CI of the estimated risk ratio is,1.8; if this cannot be done through the meta-analysis described above, it should be
accomplished in a separate, large CV safety trial
c For agents whose 95% CI upper limit falls between 1.3 and 1.8 in premarketing analysis, completion of a postmarketing trial or continuation of a
premarketing trial after approval may be needed to conclusively show that the upper limit of the two-sided 95% CI is,1.3 with a “reassuring” point
estimate of overall CV risk
*TheFDAhasgainedvaluable experience fromCVOTs andCV risk assessments intended tomeet theDecember2008 guidance. TheFDAhas acknowledged
that allowing MACE+ (a composite of CV death, nonfatal MI, or nonfatal stroke plus the less-specific end point of unstable angina requiring either
hospitalization or revascularization) in the premarket CV risk assessment to exclude a 95% CI upper limit$1.8 is acceptable because it allows for a more
reasonable sample size for evaluation. Provided no countervailing safety finding is observed, MACE+ in the premarket risk assessment strikes an
appropriate balance of safety assessment without an undue burden to companies bringing new therapies to market. However, to provide longer-term,
more reassuring CV safety data in the postmarketing setting, the exclusion of a 95% CI upper limit $1.3 should rely on the MACE composite
(CV death, nonfatal MI, and nonfatal stroke). Furthermore, these data should come from a dedicated CV trial and not from the meta-analysis of
multiple phase 2 or 3 trials (41).
16 Cardiovascular Outcomes Trials in Type 2 Diabetes Diabetes Care Volume 41, January 2018
angina or HF to the components of the
3-point MACE. Additionally, most analysis
plans permitted testing for superiority to
placebo if the noninferiority HR threshold
of,1.3 were achieved, providing an op-
portunity to show potential CV benefit.
All of the CVOTs in populations with
diabetes were designed to promote “gly-
cemic equipoise” between the treatment
groups to minimize the potentially con-
founding effect of differences in glycemic
control. Accordingly, treatment intensifi-
cation with other oral antidiabetes drugs
or insulin was more prevalent in the con-
trol groups. Even so, modest between-
group differences in A1C changes were
observed at the end of most trials, with
higher values in the placebo arms.
All primary resultswere analyzed in the
intention-to-treat (ITT) (as randomized)
or modified ITT (as treated with at least
one dose) population, with evaluations in
the on-treatment or per-protocol popula-
tions reported as sensitivity analyses.
Most study patients were receiving
near-optimal CV risk management at
baseline, as shown by a high proportion
of patients receiving antihypertensive,
lipid-lowering, and antiplatelet medica-
tions. Differences in study populations,
baseline patient characteristics, and de-
signs make it difficult to compare results
among these trials.
Effects on Cardiometabolic Risk
Factors
The impact on cardiometabolic risk fac-
tors with DPP-4 inhibitors was minimal
except for small reductions in A1C of
0.3% at study end (6–8).
The EMPA-REG OUTCOME (BI 10773
[Empagliflozin]CardiovascularOutcomeEvent
Trial in Type 2 Diabetes Mellitus Patients)
trial of the SGLT2 inhibitor empagliflozin
showed a small but statistically significant
0.3% A1C reduction at study end, simi-
lar reductions in systolic (4–5 mmHg)
and diastolic (2 mmHg) blood pressure
and weight (;2 kg), and minimal in-
creases in LDL and HDL cholesterol, with
no changes observed in heart rate (13). In
the CANVAS (Canagliflozin Cardiovascu-
lar Assessment Study) Program (14),
there were statistically significant reduc-
tions in mean A1C updated over time
(0.58%), systolic (3.93mmHg) and diastolic
(1.39 mmHg) blood pressure, and weight
(1.6 kg) and increases in LDL and HDL cho-
lesterol (4.68 and 2.05 mg/dL, respec-
tively) with canagliflozin treatment (14).
In the ELIXA trial of the GLP-1 receptor
agonist lixisenatide (9), there were statis-
tically significant reductions in A1C at
study end (0.3%), systolic blood pressure
(0.8 mmHg), and weight (0.7 kg), with a
slightly increased heart rate (0.4 bpm). In
the LEADER (Liraglutide Effect and Action
in Diabetes: Evaluation of Cardiovascular
Outcome Results) trial (10), treatment
with liraglutide was associated with a
small but statistically significant increase
in heart rate (3.0 bpm), with reductions in
mean updated A1C (0.4%), systolic blood
pressure (1.2 mmHg), and weight (2.3 kg)
and a slight increase in diastolic blood
pressure (0.6 mmHg). Similar results
were found in SUSTAIN-6 (Trial to Evalu-
ate Cardiovascular and Other Long-term
Outcomes With Semaglutide in Subjects
With Type 2 Diabetes) (11) with 0.5 and
1.0 mg doses of semaglutide; heart rate
increased by 2.0 and 2.5 bpm, respec-
tively, with robust reductions in A1C at
study end (0.7 and 1.0%, respectively), sys-
tolic blood pressure (1.3 and 2.6 mmHg,
respectively), and weight (2.9 and 4.3 kg,
respectively) and no difference in diastolic
blood pressure. Finally, in the EXSCEL
(Exenatide Study of Cardiovascular Event
Lowering) trial (12) with once-weekly
Figure 1—Completed and ongoing CVOTs (6–14,39,44–58). 3-P, 3-point; 4-P, 4-point; 5-P, 5-point. DECLARE-TIMI 58, Multicenter Trial to Evaluate the
Effect of Dapagliflozin on the Incidence of Cardiovascular Events; ESRD, end-stage renal disease; HARMONYOutcomes, Effect of Albiglutide,When Added
to Standard Blood Glucose Lowering Therapies, onMajor Cardiovascular Events in SubjectsWith Type 2 DiabetesMellitus; PIONEER 6, A Trial Investigating
the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes; REWIND, Researching Cardiovascular Events With a Weekly Incretin in
Diabetes; VERTIS CV, Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease.
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exenatide, mean updated A1C was 0.53%
lower, weight was 1.3 kg lower, and sys-
tolic blood pressurewas 1.6mmHg lower,
but heart rate was 2.5 bpm higher.
Overall, the impact of treatment inter-
ventions on cardiometabolic risk factors
was small, and the resultingeffects of these
changes on CV outcomes remain unclear.
CV Outcomes
DPP-4 Inhibitors
Five trials enrolling 49,618 patients have
been designed to evaluate the CV safety
of DPP-4 inhibitors. Three have reported
outcome results (6–8), and two are ongo-
ing (44,45).One additional trial, OMNEON
(A Study to Assess Cardiovascular Out-
comes Following Treatment With Omari-
gliptin [MK-3102] in Participants With
Type 2 Diabetes Mellitus [MK-3102-018])
(62), evaluating the investigational once-
weekly omarigliptin in 4,202 patientswith
type 2 diabetes and CVD, was terminated
as a business decision (63). Although all
three completed trials (6–8) met the pri-
mary objective of excluding an HR upper
limit $1.3, none were associated with
any suggestion of CV benefit. Likewise,
at its termination after amedian follow-up
of 96 weeks, the OMNEON trial reported
an HR of 1.00 (95% CI 0.77–1.29) for its
primary 3-point MACE end point (62).
The SAVOR-TIMI 53 (Saxagliptin As-
sessment of Vascular Outcomes Recorded in
Patients with DiabetesMellitus–Thrombolysis
in Myocardial Infarction) trial (6) with sax-
agliptin suggested an increased risk for
incident HF (HR 1.27 [95% CI 1.07–1.51],
P = 0.007 [6]), with some support pro-
vided by a trend noted in the EXAMINE
(Examination of Cardiovascular Outcomes
with Alogliptin versus Standard of Care)
trial with alogliptin (HR 1.19 [95% CI
0.90–1.58], P = 0.220 [7,59]), earning a
warning by the FDA, especially in patients
with underlying heart and kidney disease
(64).
CAROLINA (Cardiovascular Outcome
Study of Linagliptin Versus Glimepiride
in Patients With Type 2 Diabetes) (44)
was designed to establish noninferiority
of linagliptin relative to the sulfonylurea
glimepiride, thus including an active com-
parator. However, because the CV safety
of glimepiride has not been established, a
placebo-controlled trial (CARMELINA [Car-
diovascular and Renal Microvascular Out-
come Study With Linagliptin in Patients
With Type 2 Diabetes Mellitus] [45]) is
also being conducted to establish the CV
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and renal safety of linagliptin by including
an enriched population with CV risk and
evidence of renal compromise. These tri-
als may help to answer the question of CV
safety with sulfonylureas, which has been
lingering for nearly 50 years (65).
Overall, the DPP-4 inhibitors have es-
tablished MACE safety.
SGLT2 Inhibitors
The CV and renal safety of SGLT2 in-
hibitors is being evaluated in nine trials
enrolling 62,378 patients. Of these, twod
EMPA-REGOUTCOME(13) and theCANVAS
Program (14)dhave been completed,
and each reported positive CV and renal
outcomes. The other seven trials are sched-
uled for completion within the next 2–3
years (46–52).
In four SGLT2 inhibitor trials, a compos-
ite 3-pointMACE is the primary end point;
in two, a composite renal outcome is the
primary end point; and in three, a com-
posite ofHFoutcomes andCVdeath is the
primary end point in people with estab-
lished HF. Although primarily renal stud-
ies, CANVAS-R (CANVAS-Renal) (66) (data
from which were included in the com-
bined report on the overall CANVAS Pro-
gram [14]) and the ongoing CREDENCE
(Evaluation of the Effects of Canagliflozin
on Renal and Cardiovascular Outcomes in
Participants With Diabetic Nephropathy)
trial (46) also prospectively collected/are
collecting adjudicated CV outcomes, as
required by the FDA mandate. Dapa-
CKD (A Study to Evaluate the Effect of
Dapagliflozin onRenalOutcomes andCar-
diovascular Mortality in Patients With
Chronic Kidney Disease) (50) will also
evaluate CV death or HF hospitalization
in addition to the primary composite re-
nal outcome. Plans for a dedicated study
to evaluate empagliflozin on the progres-
sion of CKD were recently announced
(67). Although primarily HF studies,
Dapa-HF (Study to Evaluate the Effect of
Dapagliflozin on the Incidence ofWorsen-
ing Heart Failure or Cardiovascular Death
in Patients With Chronic Heart Failure
[49]) and EMPEROR-Reduced (Empagli-
flozin Outcome Trial in Patients With
Chronic Heart Failure with Reduced Ejec-
tion Fraction [51]), bothofwhich are in HF
patients with reduced ejection fraction,
and EMPEROR-Preserved (Empagliflozin
Outcome Trial in Patients With Chronic
Heart Failure With Preserved Ejection
Fraction [52]), in HF patients with pre-
served ejection fraction, will also prospec-
tively evaluate adjudicated renal outcomes.
EMPA-REGOUTCOME(13)wasanevent-
driven trial in patients at high CV risk
randomly treated with 10 or 25 mg
of empagliflozin or placebo, with a me-
dian observation time of 3.1 years. The
primary hypothesis was noninferiority
for the primary 3-point MACE end
point with empagliflozin (pooled doses
of 10 and 25 mg) versus placebo, with
an HR upper limit of ,1.3. The primary
end point was significantly reduced with
empagliflozin treatment (HR 0.86 [95% CI
0.74–0.99], P = 0.038). This reductionwas
driven by a significant decrease in CV
death (HR 0.62 [95% CI 0.49–0.77], P ,
0.001), with numerical, but not statisti-
cally significant, differences in nonfatal
MI (favoring empagliflozin) and nonfatal
stroke (favoring placebo). There was no
difference in the key secondary end point
of 3-point MACE plus hospitalization for
unstable angina (HR 0.89 [95% CI 0.78–
1.01], P = 0.08). Significant reductions in
prespecified end points of all-cause mor-
tality (32%) and HF hospitalization (35%)
were also observed. Superiority in terms
of CV death was large and clinically im-
portant (38% risk reduction), statistically
robust (P, 0.001), based on a large num-
ber of events (n = 309), occurring early
(within 3 months), consistently seen
with both doses across subgroups, and
established across sensitivity analyses
that accounted for silent MIs (which
were excluded from event adjudication),
nonassessable deaths, and missing data.
There was an increased rate of treatment-
emergent genital infection but no increase
in other adverse events, including diabetic
ketoacidosis, bone fractures, venous throm-
boembolism,hypoglycemicevents, amputa-
tions, and acute kidney injury. Interestingly,
reductions in CV outcomes appeared to be
unexplained by empagliflozin’s glucose-
lowering effect or by its effects on blood
pressure, weight, or uric acid, suggesting
that other mechanisms activated by
SGLT2 inhibition may contribute to this
drug’s cardioprotective effects (68–70).
Basedon this favorable benefit-risk pro-
file, the FDAapproved anew indication for
empagliflozin on 2 December 2016 “to re-
duce the risk of cardiovascular death in
adult patients with type 2 diabetes melli-
tus and cardiovascular disease” (71), a
claim that represented a clinical break-
through in treating patients with type 2
diabetes. It was also a regulatory break-
through because CV death was a second-
ary outcome but, in view of the positive
results of the primary outcome and the
robustness of the CV death data, this in-
dication was approved. On 15 December
2016, the American Diabetes Associa-
tion (ADA) endorsed this recommenda-
tion in its Standards of Medical Care in
Diabetesd2017 (72). Although EMPA-
REGOUTCOMEwas thefirst trial to demon-
strate the CV superiority of an antidiabetes
drug, more research is needed to elucidate
theunderlyingmechanisms, confirmwhether
the CV benefits are a class effect, and deter-
mine whether empagliflozin conveys a CV
benefit to patients without established CVD
or diabetes.
The CANVAS Program was originally
designed in two phases to establish the
CV protective effects of canagliflozin in
high-risk patients with type 2 diabetes
and established CVD or risk factors for
CVD (73). The first phase was included
in the meta-analysis presented to the
FDA for regulatory approval (74), which
ruled out an HR upper limit $1.8. How-
ever, these resultswere publicly disclosed
at an advisory committee meeting in
2013 after partial (group-level) unblinding
due to an observed dose-dependent in-
crease in LDL cholesterol. The FDA felt
that the lipid data necessitated public dis-
closure, and with it, the CV event data
were also disclosed, which had the poten-
tial to compromise the postmarketing
phaseof the trial to fulfill the requirement
of ruling out an HR upper limit $1.3. Be-
causeof theseextenuatingcircumstances, the
FDA accepted an integrated analysis plan,
whereby data from extended follow-up of
the CANVAS first phase before and after the
data disclosure (20 November 2012) would
be combined with new data from CANVAS-R
(66) to address CV safety as assessed by
exclusion of a postmarketing risk ratio of
1.3. A sequential hypothesis testing plan
was used, whereby a truncated integrated
data set of pooled data fromCANVAS after
20 November 2012 plus CANVAS-R was
prespecified as the principal data set for
analysis for superiority of all-cause mortal-
ity and CV death (75).
Theprimary3-pointMACEendpointwas
significantly reduced with canagliflozin
treatment (HR 0.86 [95% CI 0.75–0.97],
P = 0.02), thereby meeting the crite-
rion for noninferiority using the 1.3 risk
margin (14). It is debatable, from a rigor-
ous statistical perspective, whether an in-
ference of superiority is justified because
it was apparently not prespecified in the
testing sequence. Because the all-cause
20 Cardiovascular Outcomes Trials in Type 2 Diabetes Diabetes Care Volume 41, January 2018
mortality difference was not statistically
significant in the truncated integrated
data set (HR 0.90 [95% CI 0.76–1.07], P =
0.24), given the statistical rules of the pre-
specified hierarchical testing strategy, all
subsequent results, including the favor-
able effects on HF hospitalization, pro-
gression of albuminuria, and worsening
nephropathy, were deemed exploratory.
The point estimate for nonfatal or total
stroke was favorable for canagliflozin.
Therewasan increasedrateof treatment-
emergent genital infection as expected,
but no increase in venous thromboem-
bolism or hypoglycemic events. Diabetic
ketoacidosis was very low but slightly nu-
merically increased with canagliflozin, and
there was a nearly twofold increase in risk
for lower-leg amputation (6.3 and 3.4
events/1,000 patient-years for canagliflozin
and placebo, respectively) and a 26% rela-
tive increase in risk of bone fracture with
canagliflozin treatment. The underlying
mechanisms for these findings remain un-
clear. There are some potential biological
explanations for bone fractures, but none
for the small but significant andunexpected
increase in lower-leg amputations. Neither
bone fracture nor lower-limb amputation
has been documented with the other
SGLT2 inhibitors, so additional evaluation
is need to clarify whether this should be
viewed as a class effect.
GLP-1 Receptor Agonists
The CV safety of GLP-1 receptor agonists
has been assessed in eight trials enrolling
60,090 patients, of which four have re-
ported outcomes (9–12). A fifth trial has
been completed but not reported (53), and
the other three are scheduled for comple-
tion within the next 1–2 years (54–56).
The first reported, ELIXA (9), which was
conducted in patients with a history of
recent acute coronary syndrome (ACS),
was CV neutral, confirming the noninfer-
iority of lixisenatide with respect to a
4-point MACE but showing no beneficial
effect on any CV outcome.
The second trial, LEADER (10), demon-
strated the CV noninferiority, as well as
the statistical superiority, of once-daily
treatment with liraglutide. The reduction
in 3-point MACE (HR 0.87 [95% CI 0.78–
0.97]) with liraglutide was driven by a sig-
nificant reduction in CV death (HR 0.78
[95% CI 0.66–0.93]) with numerical, but
not statistically significant, differences in
nonfatal MI and nonfatal stroke favoring
liraglutide. The P value for the 3-point
MACE met superiority in all sensitivity
analyses. All-cause mortality, but not HF
hospitalization, was also significantly re-
duced with liraglutide. An interesting ob-
servation is the delayed separation of the
Kaplan-Meier curves (indicating time to
benefit) in LEADER (.12 months for CV
death and .18 months for all-cause
deaths and HF hospitalization) (10), sug-
gesting that the CV benefit may be con-
veyed via an impact on atherosclerotic
disease, which contrasts with the earlier
time tobenefit (,3months) in the EMPA-
REG OUTCOME trial (13). On 25 August
2017, based on the results of the LEADER
trial, the FDA approved a new indication
for liraglutide “to reduce the risk of major
adverse cardiovascular events in adults
with type 2 diabetes mellitus and estab-
lished cardiovascular disease” (76).
SUSTAIN-6 confirmed the noninferior-
ity of once-weekly treatment with 0.5
or 1 mg of the long-acting semaglutide,
which is currently under FDA review (11).
This phase 3 trial was designed to rule
out an HR upper limit$1.8 and achieved
statistical superiority (HR 0.74 [95% CI
0.58–0.95], P , 0.001), but superiority
analysis was not prespecified. The favor-
able effect on the 3-point MACE was ac-
companied by a significant decrease in
nonfatal stroke (HR 0.61 [95% CI 0.38–
0.99], P = 0.04) and a nonsignificant de-
crease in nonfatal MI (HR 0.74 [95% CI
0.51–1.08], P = 0.12), with no trend for
CV death or all-cause mortality. The risk
reduction for the primary outcome was
seen despite an increase in pulse rate,
an effect seen in all CVOTs in this drug
class to date. On 18 October 2017, the
FDA’s Endocrinologic and Metabolic
Drugs Advisory Committee voted in favor
of approval for semaglutide (77).
The fourth trial, EXSCEL (12), was per-
formed in a usual-care setting among pa-
tientswith type2diabeteswith orwithout
previous CVD. It confirmed the noninfer-
iority, but not superiority, of once-weekly
treatment with 2 mg of the long-acting
extended-release exenatide (HR 0.91
[95% CI 0.83–1.00], P = 0.06). The risk of
death from any cause was 6.9% in the
exenatide group and 7.9% in the placebo
group (HR 0.86 [95% CI, 0.77–0.97]). This
difference was considered only explor-
atory on the basis of the hierarchical test-
ing plan. The rates of CV death, fatal or
nonfatal MI, fatal or nonfatal stroke, HF
hospitalization, and ACS hospitalization;
the incidences of acute pancreatitis, pan-
creatic cancer, and medullary thyroid
carcinoma; and serious adverse events
including severe hypoglycemia did not
differ significantly between the two treat-
ment groups.
Of interest, the treatment persistence
with weekly exenatide was low, with 43%
drug discontinuation. The pragmatic na-
ture of the study design, with visits every
6 months and limited study support, may
explain the low treatment adherence and
persistence. It is remarkable that despite
this limited drug exposure and a hetero-
geneous population of whom27%had no
history of CVD, the 3-point MACE reduc-
tion of 9% came so close to reaching sta-
tistical significance, with HRs of almost all
measured parameters in the direction of
benefit.
Although full results have not yet been
published, the phase3 FREEDOM-CVO tri-
al, which evaluated continuous delivery
of exenatide and was designed for safety
purposes to accrue a limited number of
CVevents, reported in a press release (53)
that the primary objective of achieving an
HR upper limit,1.8 had been met, and a
new drug application has been submitted
to the FDA (78). Treatment persistence
could not have been an issue in this trial
given the continuous delivery of exena-
tide via a subcutaneously implanted
mini-osmotic pump.However, the limited
number of participants prevents any de-
finitive conclusions beyond meeting the
HR requirement for regulatory approval.
The heterogeneity in CVoutcomes (i.e.,
null effects with lixisenatide and exena-
tide and favorable effects with liraglutide
and semaglutide) might be mainly the re-
sult of differences in study populations,
trial designs, and treatment persistence.
However, it could also reflect differences
in pharmacokinetic andpharmacodynamic
properties (i.e., short-acting lixisenatide
is a once-daily prandial drug that acts pri-
marily on postprandial glucose, whereas
liraglutide and semaglutide are longer-
acting drugs that act mainly on fasting
glucose with a carryover effect on post-
prandial glucose) or other trial or drug
differences, including in structural simi-
larity to human GLP-1. What is clear so
far is that drugs in this class, if tolerated,
are safe, and, if affordable, should be con-
sidered more often for type 2 diabetes
management.
Other Drugs
PPARAgonists. Two trials to determine the
CV effects of aleglitazar, a dual activator
of PPAR-a and -g, were started but
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terminated early due to safety concerns
and futility for efficacy. The AleCardio trial
(79) enrolled 7,226 patients with a recent
ACS event. At its termination after a me-
dian follow-up of 104 weeks, several CV
and non-CV safety concerns were identi-
fied, including increased risks of HF and
bone fractures, decreased estimated glo-
merular filtration rate (eGFR), and evi-
dence of increased risk of gastrointestinal
bleeding, which was unanticipated. The
ALEPREVENT trial (80) enrolled 1,999 pa-
tients with prediabetes or type 2 diabetes
and established stable CVD. At its termina-
tion after a brief treatment period (58 6
38 days), aleglitazar was associated with
increased incidences of hypoglycemia
and muscular events.
As previously mentioned, the IRIS trial
of the TZD pioglitazone (39,40) reported a
significant 24% reduction in its composite
end point of fatal or nonfatal stroke orMI
compared with placebo after 4.8 years of
follow-up in 3,876 insulin-resistant sub-
jects with a recent ischemic stroke or
transient ischemic attack but without di-
abetes. No between-group difference in
all-cause mortality was found.
TOSCA.IT (Thiazolidinediones or Sulfo-
nylureas Cardiovascular Accidents Inter-
vention Trial) (81), a trial comparing the
CV safety of pioglitazone to a sulfonyl-
urea in 3,028 patients, was terminated
on the basis of a futility analysis after a
median follow-up of 57months. A total of
213 events were adjudicated and in-
cludedintheCVanalysis.Theprimarycom-
posite end point (nonfatal MI, nonfatal
stroke, all-cause death, and urgent coro-
nary revascularization) showed no signif-
icant difference between pioglitazone
and sulfonylurea treatment (HR 0.96
[95% CI 0.74–1.26], P = 0.790). Pioglita-
zone was associated with a reduced risk
of severe hypoglycemia (,0.2 vs. 2.0%,
P, 0.0001) and moderate hypoglycemia
(10 vs. 32%, P , 0.001). Despite the fact
that pioglitazone showed evidence of CV
benefit in both the PROactive (38) and
IRIS (39,40) trials, this study failed to rep-
licate the treatment benefit, albeit in a
lower-risk population. It should be noted
that TOSCA.IT was ultimately underpow-
ered, with a substantial percentage of pa-
tients not taking their assigned medica-
tion because of concerns that emerged
during the trial about a possible link
between pioglitazone and bladder can-
cer. A longer and larger active-controlled
study (e.g., CAROLINA [44]) should shed
more light on the relative CV effects of
sulfonylureas.
Insulin. Although undertaken 5 years be-
fore the 2008 FDA guidance and thus out-
side of the primary focus of this article,
the ORIGIN Trial (Outcome Reduction
with an Initial Glargine Intervention)
(82,83), established the neutral CV effects
of insulin glargine compared with stan-
dard glycemic care in 12,537 participants
with CV risk factors plus impaired fasting
glucose, IGT, or type 2 diabeteswhowere
followed for a median of 6.2 years.
More recently, DEVOTE (A Trial Com-
paring Cardiovascular Safety of Insulin
Degludec Versus Insulin Glargine in Pa-
tients With Type 2 Diabetes at High Risk
of Cardiovascular Events) (57), involving
7,637 patients with established CVD
and amean diabetes duration of 16 years,
confirmed the CV safety of insulin deglu-
dec compared with insulin glargine (HR
0.91 [95% CI 0.78–1.06], P = 0.21). This
study was conducted after the FDA
required a preapproval degludec CVOT
based on the results of its phase 2 and
3meta-analysis (43). Degludecwas statis-
tically superior with regard to hypoglyce-
mia risk, with a lower rate of both severe
and nocturnal severe hypoglycemia (by
40 and 53%, respectively; P , 0.001 for
both comparisons). These findings corre-
sponded to absolute incidence rates for
severe hypoglycemia of 4.9 and 6.6% and
for severe nocturnal hypoglycemia of 1.0
and 1.9% for degludec and glargine, re-
spectively. Interestingly, despite the dif-
ferences in severe hypoglycemia, no
differences in CV mortality were found.
a-Glucosidase Inhibitors. The ACE trial of
acarbose (58) in 6,522 Chinese patients
with coronary heart disease and IGT
showed no relative risk reduction for the
primaryoutcomeof 5-pointMACE (3-point
MACE plus hospitalization for unstable an-
gina or HF) (HR 0.98 [95% CI 0.86–1.11],
P = 0.73) or for any secondary end points
compared with placebo. Although acar-
bose treatment did not reduce CV risk,
a modest reduction in incident type 2
diabetes was observed (HR 0.82 [95%
CI 0.71–0.94], P = 0.005) over a median
follow-up of 5 years with a dose of 50 mg
three times daily.
Although ORIGIN, IRIS, DEVOTE, and
ACE were not initiated as a direct result
of the 2008 FDA guidance and OMNEON,
AleCardio, ALEPREVENT, and TOSCA.
IT were terminated early, these trials none-
theless contributed important insights
to our overall understanding of the CV
effects of pharmacotherapies for type 2
diabetes.
Benefits and Challenges of the Current
CVOT Design
Benefits
Trials have shown that insulins glargine and
degludec, sitagliptin, alogliptin, saxagliptin,
lixisenatide, and once-weekly exenatide
(6–9,12,57,82,83) have neutral effects
on MACE outcomes, thereby supporting
the use of these drugs when needed
to improve glycemic control with the goal
of limiting microvascular complications
without increasing CV risk. Well-designed
and adequately powered CVOTs for other
antidiabetes drugs have also provided valu-
able information beyond their primary
safety purpose. The evidence for CV benefit
from empagliflozin, canagliflozin, liraglutide,
and possibly semaglutide versus placebo
(10,11,13,14), supplemented by data
from other studies, already has prompted
reconsideration of treatment guidelines
(70,84) and is likely to alter clinical prac-
tice and reduce CV events and deaths
among people similar to those enrolled
in these trials.
Other insights from these trials have
derived from secondary end points, which
are in some cases less statistically robust
but nonetheless of potential importance.
Notably, recent CVOTs have focused
attention on the pressing problem of
HF, which affects older people with dia-
betes more frequently than MI (85).
Empagliflozin caused an early, large, and
somewhat unexpected reduction in hos-
pitalization for or death from HF (HR
0.61 [95% CI 0.47–0.79], P , 0.001) (86).
Canagliflozin also had favorable effects on
HF, although perhaps of lessermagnitude
(14). Less certain, but also of interest, is
the incidental observation of increased
HF with saxagliptin and a consistent non-
significant trend with alogliptin, despite
no effect on other CV end points (6,59).
If this harm is confirmed, it will draw at-
tention to previously unsuspected effects
of and differences amongDPP-4 inhibitors,
which block cleavage of many circulating
peptides and thusmayhave various down-
stream effects (either benign or harmful)
other than reducing clearance and increas-
ing blood levels of GLP-1.
Another clinically important benefit of
these trials has been assessment of the
effect of the tested drugs on kidney dis-
ease, itself a CV risk factor. For example,
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empagliflozin (HR 0.61 [95% CI 0.53–
0.70], P , 0.001) (60), canagliflozin (HR
0.60 [95% CI, 0.47–0.77], P , 0.0001)
(14), liraglutide (HR 0.78 [95% CI 0.67–
0.92], P = 0.003) (10), and semaglutide
(HR 0.64 [95% CI 0.46–0.88], P = 0.005)
(11) all reduced progression of renal dis-
ease more than would be expected from
the improvements in glucose and blood
pressure provided by these drugs. Impor-
tantly, the renal benefits of the SGLT2 in-
hibitors extended to actual deterioration of
renal function as denoted by a doubling of
serum creatinine or major reduction in
eGFR, whereas those of the GLP-1 receptor
agonists appear to be mainly on the pro-
gression to macroalbuminuria. However,
semaglutide appears to have a deleterious
effect of diabetic retinopathy, possibly re-
lated to rapid anddramatic improvement in
glycemic control inpatientswithpreexisting
retinopathy (11). A lesser trend for ad-
verse eye outcomes with liraglutide re-
quires further assessment (10).
Together, these findings have ener-
gized the medical community. Many CV
experts appear to have revised their pre-
vious skepticism about the potential for
CV benefits from diabetes-specific thera-
pies. Diabetes researchers are exploring
mechanisms that may explain the clinical
effects first noted in these trials. The find-
ings with empagliflozin and canagliflozin,
which alter renal clearance of sodium as
well as glucose and thus cause hemody-
namic changes, have led to reconsidera-
tion of abnormalities in salt and water
balance that are intrinsic to diabetes, an
area long inactive in physiological re-
search (87). Another provocative pro-
posal is that injured myocardial and
renal tissues may benefit from access to
the energy supplied by modestly higher
circulating ketone levels during treatment
with SGLT2 inhibitors (68,69). These hy-
potheses open new areas of investigation
for both clinical and basic research.
Challenges
Aside from obvious questions about com-
peting priorities for allocation of financial,
clinical, and professional resources and, in
somecases, delays in regulatory approval,
the currently advised structure for CVOTs
has several practical limitations (Table 4).
The most serious of these is the lack of
generalizability of findings to the entire
population of people with diabetes.
As currently performed, randomized
controlled trials (RCTs) requireparticipants
to have certain inclusion characteristics.
They must be able to provide informed
consent, agree to attend the study site
for an extended period of time, and be
physically able to do so. To answer ques-
tions of safety and efficacy, they must be
at high risk to experience the outcome in
question (in this case, a CV event or death)
in order to provide an adequate number of
events in an acceptable period of time.
They cannot be entirely representative of
the general population, and therefore the
findings of such trials can be extrapolated
to a wider population only with consider-
able caution. As an example, the EMPA-
REG OUTCOME trial provides reasonable
confidence that people with type 2 diabe-
tes and a history of previous CVD are likely
to benefit from empagliflozin therapy in
the same manner as did the patients in
the trial itself (13). However, there is less
certainty that empagliflozin will similarly
improve outcomes for individuals with di-
abetes and no history of CVD or for those
with CVD but without diabetes. In the
CANVAS Program, one-third of partici-
pants had only CV risk factors and no evi-
dence of CVD. Perhaps the less impressive
but still positive outcomes with canagliflozin
in this research program may be related
to this population subset that might
require longer drug exposure in a longer-
term trial (14). Notably, a subgroup anal-
ysis of the LEADER trial suggested the
hypothesis that liraglutide effectively
lowered CV risk only in peoplewith estab-
lished CVD (HR 0.83 [95% CI 0.74–0.93]
compared with HR 1.20 [95% CI 0.86–
1.67] in those without CVD, with a signif-
icant unadjusted interaction P value of
0.04) (10). Due to the large number of
statistical tests that were performed for
subgroups, the possibility that this was a
chance observation cannot be excluded.
Nonetheless, the FDA-approved indica-
tion for liraglutide for CV risk reduction
was restricted only to those with estab-
lished CVD.
In addition, the present CVOT design
has serious limitations related to the
natural histories of diabetes and CVD.
Because the concerns of regulatory
agencies, pharmaceutical companies,
health systems, and in many cases, indi-
viduals with diabetes have relatively
short timelines, current CVOTs address
only short-term outcomesdnot those
occurring .5 years after the onset of
treatment. However, several lines of evi-
dence argue for the importance of longer-
term follow-up.
Experience from the UKPDS and DCCT/
EDIC (Epidemiology of Diabetes Interven-
tions and Complications) cohorts, which
were treated early in the course of diabe-
tes, shows that importantmedical compli-
cations of diabetes, including blindness,
renal failure, amputation, CV death, and
others, do not usually appear in the first
5 years. Rather, each has a characteristic
and much longer development timeline
(26–28). In the case of CVD, significant
numbers of CV events in the UKPDS and
DCCT/EDIC did not accumulate until af-
ter .10 years of follow-up. In part be-
cause of the slow accrual of events, the
apparent CV benefits of early randomiza-
tion to intensive glycemic control were
not observed until long after initiation
of treatment. The CV benefits likewise oc-
curred long after the change in A1C dif-
ference disappeared after cessation of
randomized treatment, leading to the
concept of a “legacy effect,” for which
there is no proven explanation. These
long-term benefits were shown through
observational and possibly incomplete
data within which residual confounding
cannot be excluded, so they cannot con-
fidently be attributed only to glycemic
control. Nevertheless, a mechanism plau-
sibly underlying the legacy effect is a re-
duction of glucose-related changes of
vascular tissue structure, occurring during
intensive glycemic therapy but persisting
thereafter, thatmayhave slowed theearly
progression of atherosclerosis and led to a
much later reduction in overt CV events.
Whether any nonglycemic effect of treat-
ments in these trials contributed to this
benefit cannot be determined.
This view is consistentwith the findings
of other large trials of short-term glucose-
lowering strategies using similar treatments
thatwereapplied later in thenatural history
of type 2 diabetes. In ACCORD (20,88) and
VADT (22,29), there were only modest re-
ductions in some secondary CV end points
in patients with a long duration of diabetes
and high CV risk, but in ACCORD, there
was an unexplained early increase in mor-
tality. Specifically, very intensive glucose-
lowering treatment goals achieved mainly
with the use of metformin, sulfonylureas,
TZDs, and intensive insulin regimens in these
trials were unable to diminish the risk of
events in patientswhoalreadyhadadvanced
CV pathology.
The failure of targeting very intensive
glucose lowering in ACCORD and VADT
highlights the benefits of treatment with
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Table 4—Limitations of current CVOT structure and opportunities for improvement
Current limitations
Lack of generalizability Current CVOTs include participants who are at high risk for a CV event or death and thus
are not representative of the larger population.
Short timeline for assessing potential benefits CV benefit may not become apparent until long after initiation of treatment. Current
CVOTs do not assess outcomes occurring .5 years after the onset of treatment.
Short timeline for assessing potential harm CVOTs lasting,5 years are not likely to detect risks that may become apparent only after
years of treatment. This may be especially concerning for agents with complex
mechanisms of action.
Placebo-controlled design Nearly all CVOTs to date have tested one drug against placebo, with both groups
attempting to attain comparable glycemic control using regimens that also include
other medications. Problems with this design include 1) comparable glycemic control
generally has not been achieved and the lower A1Cs found with the study drug may
contribute to CV benefits, 2) some drugs used in the comparison groupsmay themselves
have an adverse effect on CV events, and 3) the CV benefits found with four agents to
date make the future use of placebo ethically challenging.
Opportunities for improvement
Lower-risk, more diverse populations Primary intervention trials in lower-risk populations could determine whether diabetes
medications offer CVprotection for thosewhodonot yet haveCVD. Thiswould require
larger and/or longer studies but would yield valuable information with regard to CVD
prevention.
Longer-term follow-up Trial designs that prespecify longer-term follow-up could better identify longer-term
safety issues and late beneficial effects, produce better cost-effectiveness data, and
improve understanding of changing treatment requirements over time. Such a design
would require new consent procedures to permit lifelong follow-up, strategies to
increase therapy adherence and persistence, expanded use of EMRs, and innovative
statistical approaches to permit serial reporting of key clinical outcomes over time.
Active comparators Using an active comparator instead of placebo could address the drawbacks of placebo-
controlled trials but will require sufficient knowledge of the CV impact of the
comparator to avoid confounding interpretation of the results. Although challenging,
thismay become feasible as understanding of the CV safety of newer agents increases.
Across-trials consistency in enrollment criteria and the capturing of baseline patient
characteristics will facilitate such efforts.
Innovative designs Adoptionof factorial or adaptivedesigns, superiority trials, trials embeddedwithinhealth
care systems or networks, and/or employment of “big data” to dissect the effects of
new diabetes medications may provide practical opportunities for further investigation.
Standardized definitions Standard definitions of important safety and microvascular outcomes would facilitate
better comparisons among agents. Collaborative efforts should be made to
standardize definitions of high-priority safety and microvascular outcomes, akin to
those established for CV outcomes.
Modification of end points and analyses Incorporating weighted composite end points that include estimation of the severity of
events, aswell asmultiple events in the samepatient,may yieldmorenuancedfindings
in future studies. The design of trials for new agents should be informed by data from
previousCVOTswithinthesamedrugclass. Important secondaryoutcomeswith robust
statistical findings that are biologically plausible and supportable by external evidence
should be independently considered even if primary composite outcomes are not
achieved. Such approaches would require buy-in from regulatory bodies and
mechanismstoensureequity fordevelopersoffirst-in-class interventionsand/or those
who willingly adopt more complex trial designs. How best to incorporate predefined
safety concerns into primary analyses should also be considered.
Establishment of biorepositories Future trials should obtain informed consent to store participants’ biological samples in
case unexpected results warrant further investigation. Such biorepositories could
increase opportunities to investigate various mechanisms contributing to CV events and
key subgroups and will become increasingly important for subsequent biomarker, gut
microbiota, and genomic analyses to facilitate precision medicine opportunities.
Enhanced efficiency and cost-sharing options Conducting a CVOT for each newdiabetes drug is cumbersome and expensive. Strategies
to enhance trial efficiency, such as collecting CVoutcomesdata fromtrials designed for
other purposes, should be strongly considered, as should newmodels for cost-sharing
among pharmaceutical, governmental, and other organizations.
Involvement of patients and advocacy organizations Involving patients and their advocates in designing future trials will help to ensure that
patients’ views and wishes are taken into account and that patient-related outcome
measures are fully integrated. Such efforts would likely increase patient buy-in and help
to minimize discontinuation, improve treatment adherence and persistence, and avoid
missing data.
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empagliflozin, canagliflozin, liraglutide,
and semaglutide in their respective CVOTs.
Favorable CV effects with these drugs pre-
sumably resulted fromeffects beyond sim-
ply lowering glucose in patients with
advanced diabetes, except perhaps in
the trial testing semaglutide, during which
a pronounced A1C reduction occurred
in the group receiving active therapy.
Whether the beneficial effects of these
drugs would be similar or different if they
were initiated closer to the time of diabetes
diagnosis and earlier in the course of CVD
development remains to be seen.
The current CVOT design also provides
only limited objective information about
harmful outcomes that occur .5 years
after an intervention. Whether the new
antidiabetes drugs currently being evalu-
ated have risks thatmay appear only after
years of therapy is unknown, but CVOTs
with a duration of,5 years are not likely
to detect them. Concerns may be greater
for therapeutic drugswith complexmech-
anisms of action that are not currently
well understood, including TZDs, DPP-4 in-
hibitors, and (despite their strong short-
term protective effects) SGLT2 inhibitors.
CVOTS OF THE FUTURE:
OPPORTUNITIES FOR
IMPROVEMENT
As previously noted, the completed
CVOTs have yielded some important in-
formation about both safety concerns
and potential medical benefits. Regarding
safety, the increased risk of HF hospitali-
zation with saxagliptin in SAVOR-TIMI
53 (6) and a nonsignificant trend with
aloglipitin in EXAMINE (7,59) resulted in
the addition of new safety warnings to
the labels of those medications (64).
Given these safety signals for HF, which
were unexpected from the registration
trials, it is likely that studies of individual
antidiabetes drugs will continue to be
required.
Further, four of the completed tri-
als (LEADER, SUSTAIN-6, EMPA-REG
OUTCOME, and the CANVAS Program)
reported clinically relevant relative risk
reductions ofMACE outcomes in patients
withhighCVrisk (Table 5) (10,11,13,14,60).
Although it is inherently inappropriate to
compare results among trials because
they are conducted in different popula-
tions, with different protocols, and at dif-
ferent sites, the numbers needed to treat
(NNTs) to prevent a MACE occurrence in
EMPA-REGOUTCOME (63over 3.1 years),
LEADER (53 over 3.8 years), and SUSTAIN-
6 (44 over 2 years) were similar to those
observed for widely recommended thera-
pies to prevent CVD such as lipid lowering
with statins, antihypertensive therapy,
and aspirin (89). These three trials, to-
gether with similar but more controver-
sial findings in the CANVAS Program,
support an early and evolving case for
the use of these antihyperglycemic ther-
apies in patients with type 2 diabetes and
evidence of clinical CVD who are .50
years of age.
Although the trials conducted thus far
appear to both satisfy the FDA guidance
recommendations and provide additional
useful information, there are clearly op-
portunities for improvement (Table 4).
The next generation of diabetes trials
should be smarter, simpler, and innova-
tively designed to make more efficient
use of resources and produce more gen-
eralizable results while still addressing
safety issues. The design and conduct of
future trials should be standardized
enough to permit reliable between-trial
comparisons but also nimble enough to
explore unanticipated safety concerns
that may arise. In pursuing these goals,
some modifications to the current CVOT
noninferiority trial design, outlined be-
low, are worthy of consideration.
Lower-Risk and More Diverse
Populations
Incorporation of recent trial findings into
diabetes care guidelines has been limited
to date, in part because the populations
studied were selected for high CV risk.
Although this practice is consistent with
FDA recommendations and essential to
demonstrate safety, it remains unclear
whether results seen in high-risk patients
are translatable to patients with a shorter
duration of diabetes or without estab-
lished CV complications.
Enrollment of very high-risk subjects
also may hamper the ability of trials to
detect a benefit from drug therapy. As
examples, the ELIXA trial of lixisenatide
(9) and the EXAMINE trial of alogliptin
(7) exclusively recruited patients with a
recent hospitalization for an acute coro-
nary event. Such patients are easy to
identify based on hospital records and
are likely to have a high number of fu-
ture MACE events. Thus, such trials may
be completed more quickly than those
enrolling patients with more stable CVD.
However, this strategymay fail to detect a
beneficial effect of the intervention stud-
ied because the CVD is too advanced, the
drug exposure is too short, and/or the
early events may be less amenable to
the intervention.
The best way to demonstrate benefit
might be to select lower-risk patientswho
have not yet manifested CVD to find out
whether their likelihood of developing
CVD can be reduced. To achieve a statisti-
cally significant number of MACE events,
this will require larger and/or longer stud-
ies but would yield valuable information
about CVD prevention.
Longer-Term Follow-Up
Trial designs that prespecify longer-term
follow-upmaybedesirable to identify any
longer-term safety issues and beneficial
effects that are either slowly evolving or
resulting from a legacy effect of earlier
treatment. Toward that end, innovative
consent procedures that permit lifelong
follow-up should be explored, as should
strategies to increase patient adherence
to and persistence with assigned therapy.
The ability to capture medication adher-
ence and relevant clinical and laboratory
data will be crucial and should be facili-
tated by use of more sophisticated elec-
tronic medical records (EMRs).
Statistical approaches would need to
bedeveloped (andapprovedby regulatory
bodies) to permit robust assessment of
key clinical outcomes over an extended
timescale. For example, a trial could pro-
vide definitive early information on the de-
gree of glucose lowering achieved (e.g., at
1 year) and also be powered to assess the
impact of an intervention on a primary
clinical outcome at a later time (e.g., at
3 years). Continued follow-up thereafter
could examine recurrent or less frequent
clinical outcomes, maximize collection of
safety data, and better assess the durabil-
ity of the glucose-lowering effect.
Even a few such trials could yield a rich
harvest of clinically relevant information to
better inform clinical guidelines and ther-
apeutic choices for patients and produce
more robust cost-effectiveness data for
health care providers. Longer trials would
also provide a better understanding of the
evolution of treatment requirements over
time, especially if participants are random-
ized to specific therapeutic sequences.
Active Comparators
Another difficulty in interpreting and ap-
plying the results of most CVOTs com-
pleted to date concerns comparing the
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drug in question to placebo, with both
groups attempting to attain comparable
glycemic control using regimens that in-
clude other medications. There are sev-
eral problems with this design. First, in
general, comparable glycemic control is
not achieved, with the study drug group
usually having lower A1C values. Such dif-
ferences might contribute to any CV ben-
efits seen. Second, some drugs usedmore
frequently in the comparison groups may
themselves have CV effects. Third, mov-
ing forward, it may not, for ethical rea-
sons, be possible to restrict background
use of drugs that have recently been
shown to have beneficial effects.
However, using an active comparator
as a control will require sufficient knowl-
edge of the CV impact of the comparator
to avoid confounding interpretation of
the results. Although challenging, this
may become feasible as our understand-
ing of the CV safety of newer antidiabetes
drugs increases. Future trialsmay success-
fully assess the impact of a new drug com-
pared with a previously tested drug if the
newer trial enrolls a patient population
and adopts a design that is similar to
that with which the comparator drug was
studied. Combinations of drugs known to
be cardioprotective may also need to be
tested to explore whether the CV benefits
are compounded. Between-trial consis-
tency in study design, enrollment criteria,
and ascertainment of clinical data will fa-
cilitate these efforts.
Innovative Designs
Creative trial designs likely will be needed
to fully address current concerns. In addi-
tion to traditional RCTs, factorial or adap-
tive designs, superiority trials, trials
embedded within health care systems or
networks, and/or employment of “big
data” to dissect the effects of new diabe-
tes medications may provide practical
opportunities for further investigation.
Factorial designswould increase efficiency
by allowing simultaneous testing of multi-
ple interventions, and superiority trials
would put greater emphasis on potential
benefits of therapy and likely make re-
cruitment easier by increasing the value
proposition forparticipants. Pragmatic de-
signs that embed studies within health
care systems’ EMR platforms would pro-
vide a natural conduit for conducting long-
term posttrial observational follow-up
studies. However, lessons from EXSCEL
(12) must be considered to avoid having
low treatment persistence in suchdesigns.
EmbeddingRCTs into routineclinical care
would also enable the multidimensional
collection of additional clinical outcomes
relevant to diabetes that are not collected
routinely in current trials because of cost
and complexity. Such outcomes include
rates of cancer, bone fractures, depression,
and dementia, as well as unexpected off-
target side effects undetected during con-
ventional drugdevelopmentprograms. This
would extend assessment of safety beyond
CV safety and include long-term durability
of effects. Sample sizes could be much
larger using the embedded trial approach
becauseof lower costs perpatient, enabling
more powerful assessments of the hetero-
geneity of treatment effects. Trials of this
nature also could be crucial in realizing the
goalofprecisionpharmacotherapy in type2
diabetes, should different classes of drugs
or specific drugs within classes be found to
be better for patients with different clinical
characteristics (31). However, defining the
randomization process to avoid con-
founders and any imbalances between
the groups studied will be crucial.
Although registries or EMRs may af-
ford the opportunity for large, pragmatic,
and relatively inexpensive trials, the suc-
cess of such trials likely will depend on
having a simple intervention and an ap-
propriate health systemwith an adequate
EMR, as is the case with the ongoing
Table 5—Risk reduction in four completed trials showing evidence of CV benefit
LEADER (10) SUSTAIN-6 (11) EMPA-REG OUTCOME (13,60) CANVAS Program (14)
Subjects (n) 9,340 3,297 7,020 10,142
Mean age (years) 64.3 64.6 63.1 63.3
Diabetes duration (years)* 12.8 13.9 57% .10 13.5
Mean baseline A1C (%) 8.7 8.7 8.1 8.2
Mean placebo-corrected A1C difference (%)† 20.4 20.7 (0.5 mg dose) 20.24 (10 mg dose) 20.58
21.0 (1.0 mg dose) 20.36 (25 mg dose)
Median follow-up duration (years) 3.8 2.1 3.1 2.4
3-point MACE RRR (%) 13 26 14 14
3-point MACE ARR (%) 1.9 2.3 1.6 d‡
CV death RRR (%) 22 2 38 4§; 13|
Nonfatal MI RRR (%) 12 26 13 15
Nonfatal stroke RRR (%) 11 39 +24 10
All-cause mortality RRR (%) 15 +5 32 13§; 10|
HF hospitalization RRR (%) 13 +11 35 33
Worsening nephropathy RRR (%)¶ 22 36 39 40
Boldface type indicates statistical significance. +, increased relative risk;d, not reported; ARR, absolute risk reduction; RRR, relative risk reduction.
*Reported as mean in all trials except EMPA-REG OUTCOME, which reported percentage of population with diabetes duration.10 years. †For LEADER
and the CANVAS Program, difference was updated over time; for SUSTAIN-6 and EMPA-REG OUTCOME, difference was at study end. ‡Data needed to
calculate ARR in 3-point MACE (specifically the NNT) were not reported for the CANVAS Program; instead this trial reported an incidence rate difference
of 4.6 per 1,000 patient-years for canagliflozin vs. placebo. §Truncated integrated data set (refers to pooled data from CANVAS after 20 November
2012 plus CANVAS-R; prespecified in treating hierarchy as the principal data set for analysis for superiority of all-cause mortality and CV death in the
CANVAS Program). |Nontruncated integrated data (refers to pooled data from CANVAS, including before 20 November 2012 plus CANVAS-R. ¶Worsening
nephropathy is defined as the new onset of macroalbuminuria (urine albumin creatinine ratio.300 mg/g) or a doubling of the serum creatinine level
and an eGFR rate of#45 mL/min/1.73 m2, the need for continuous renal-replacement therapy, or death from renal disease in LEADER, SUSTAIN,
and EMPA-REG OUTCOME and as 40% reduction in eGFR, renal-replacement therapy, or death from renal causes in CANVAS. This outcome was a
prespecified exploratory adjudicated outcome in LEADER, SUSTAIN-6, and CANVAS but not in EMPA-REG OUTCOME.
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ADAPTABLE (Aspirin Dosing: A Patient-
Centric Trial Assessing Benefits and Long-
term Effectiveness) trial of aspirin therapy
for atherosclerotic CVD (90). As men-
tioned above, irrespective of trial design,
treatment randomization will remain cru-
cial to determining a medication’s effect
without undue bias.
Standardized Definitions
Safety and efficacy comparisonswould be
greatly enhanced by standardizing the
definitions of important outcomes. The
strategies and definitions used to identify
events such as pancreatitis, pancreatic
malignancy, progression of retinopathy,
andworsening of renal function have var-
ied considerably among the CVOTs con-
ducted to date. Collaborative efforts
should be made to generate definitions
for high-priority safety and microvascular
outcomes, akin to those established for
CV outcomes.
Modification of End Points and
Analyses
In light of the noted differences in effects
of drugs on components of MACE com-
posite end points, it may be desirable to
reassess the end points and primary anal-
yses to be adopted in future studies to
provide a more nuanced look at CV out-
comes. Trials likely will still be powered
based on the time to the first primary end
point, despite disadvantages that include
possible heterogeneity of the composite
components, results drivenby components
of lesser importance, and insufficient
power to draw definitive conclusions for
all components of the composite (91). To
address these limitations, alternative an-
alytic strategies such as weighted com-
posite outcomes (92) and the win ratio
approach (93) should be considered. To
better capture the full impact of treat-
ments, subsequent and recurrent events
also need to be evaluated for both bene-
fits and risks using validated statistical ap-
proaches (94,95). When testing drugs
within the same class, data from previous
trials should be used to inform both the
design and sample size requirements,
with a Bayesian approach considered to
potentially limit sample sizes to more
manageable and less costly proportions
without compromising study power. Im-
portant secondary outcomes, especially
mortality or serious irreversiblemorbidity
events, should not be dismissed even if
the primary composite outcomes are not
achieved; they should be independently
considered, especiallywhen the statistical
findings are robust, biologically plausible,
and supportable by external evidence.
This way forward would require buy-in
from regulatory bodies, as well as mech-
anisms to ensure equity for developers of
first-in-class interventions and/or those
who willingly adopt more complex trial
designs.
Another challenge is how best to incor-
porate predefined safety concerns into
the primary analysis. One possibility is
to add safety issues as components of
the primary composite outcome if the in-
cluded safety and efficacy components
can be weighted appropriately to reflect
their clinical importance. Such a com-
bined end point would then reflect the
intervention’s overall net clinical benefit
to the patient. If there is adequate power,
it may be more desirable to evaluate key
efficacy and key safety outcomes sepa-
rately as predefined coprimary end points,
with superiority and noninferiority analy-
ses respectively, as was done in EXSCEL
(12). In general, however, the FDA typically
prefers trials to establish efficacy and
safety separately, with approval based
on whether efficacy (benefit) outweighs
safety (harm).
Establishment of Biorepositories
Many differentmechanisms contribute to
the occurrence of CV events, including
atherosclerosis, hemodynamic changes,
arrhythmias, and, for strokes, hemorrhagic
mechanisms. To gain additional insight
into both mechanisms and subgroups, it
would be desirable for future trials to
have informed consent to store biological
(i.e., serum, urine, fecal, andDNA) samples
in case unexpected results warrant further
investigation or for additional hypothesis-
generating studies. Greater use of patient
phenotyping, genotyping, andmetabolomic
data, similar towhat isnowbeingdone inthe
field of oncology,may help to better identify
predictors of benefit or harm that so far
have escaped detection. Biorepositories
will be of key importance in this regard,
as well, by allowing for subsequent bio-
marker, gutmicrobiota, and genomic anal-
yses to facilitate future precision medicine
opportunities.
Enhanced Efficiency and Cost-Sharing
Options
The current system for evaluating the CV
safety of new diabetes drugs, in which
each is assessed individually in a large,
long-termCVOTfundedbyapharmaceutical
sponsor, is cumbersome and expensive.
Strategies to enhance the efficiency of
trials, such as collecting CV outcomes
data from trials designed for other pur-
poses, should be strongly considered. Al-
though evidence that the expense of such
studies is suppressing innovation in new
diabetes drug development is lacking, it is
conceivable that, if the cost of CVOTs
were reduced, more innovative research
could be supported. Thus, models for
cost-sharing among pharmaceutical, gov-
ernmental, and other organizations
should be explored.
Involvement of Patients and Advocacy
Organizations
When designing future trials, all stake-
holders should be involved. The direct
involvement of patients and their advo-
cates will be vitally important to ensure
that patients’ views and wishes are taken
into account and that patient-related out-
come measures are fully integrated.
There is some concern, however, that
patient-reported outcome measures are
not standardized, limiting comparisons
between studies. Efforts to improve
patients’ understanding of clinical trials
and to enlist the help of patients in de-
veloping trial information literature and
consent processes might improve pa-
tients’ willingness to participate as sub-
jects. The importance of minimizing
participant discontinuation, improving
study drug adherence and treatment
persistence, and avoiding missing data
cannot be overstated when seeking to
obtain definitive trial outcomes. The rapid
growth of digital health and monitoring
devices with Internet connectivity may of-
fer further opportunities to access patient-
specific outcomes or provide mechanistic
insights (29,96).
CONCLUSIONS
The 2008 FDA guidance for diabetes drug
development greatly increased the collec-
tion of data on conventional CVoutcomes
of treatment. Studies completed to date
and those now under way are providing
strong evidence for CV benefit for several
drugs and reassurance about the lack of
CV risk for many others. In addition, they
have yielded further information on
non-CV benefits, such as reduction of re-
nal disease, and potential harms, such as
HF and lower-limb amputations. This
information has built a strong founda-
tion of outcomes evidence that is truly
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transforming diabetes care. The informa-
tion on improvedCVoutcomes for specific
antidiabetes drugs should be considered
in revised clinical treatment recommenda-
tions, given that cardioprotection is an
added benefit.
However, after nearly a decade of ex-
perience with CVOTs designed on the ba-
sis of the 2008 guidance, it is time to
reevaluate how best to conduct such tri-
als. Future trialsmight benefit from focus-
ing on populations more typical of those
seen in routine care, with longer duration
of follow-up, greater consistency in the
ascertainment of outcomes, and improved
statistical methods for analysis. In addi-
tion, greater efficiency and relevance to
clinical practice might be obtained by
collaboration of various stakeholders in
health caredincluding pharmaceutical
companies, regulatory groups, insurers,
health systems, consumer advocates,
and peoplewith diabetes themselvesdin
the conduct of trials, perhaps by embed-
ding clinical protocols within health sys-
tems. It is to be expected that future
trials, like those already completed, will
provide both answers to the primary re-
search questions posed and new insights
regarding previously unexpected benefits
and risks.
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